175 related articles for article (PubMed ID: 20936466)
1. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.
Herzog M; Storch CH; Gut P; Kotlyar D; Füllekrug J; Ehehalt R; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):1-11. PubMed ID: 20936466
[TBL] [Abstract][Full Text] [Related]
2. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
Storch CH; Ehehalt R; Haefeli WE; Weiss J
J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
[TBL] [Abstract][Full Text] [Related]
3. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
[TBL] [Abstract][Full Text] [Related]
4. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
[TBL] [Abstract][Full Text] [Related]
5. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.
Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A
Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464
[TBL] [Abstract][Full Text] [Related]
6. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
[TBL] [Abstract][Full Text] [Related]
7. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
8. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.
Ni Z; Bikadi Z; Shuster DL; Zhao C; Rosenberg MF; Mao Q
Biochemistry; 2011 Sep; 50(37):8057-66. PubMed ID: 21854076
[TBL] [Abstract][Full Text] [Related]
9. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
[TBL] [Abstract][Full Text] [Related]
10. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).
Mohrmann K; van Eijndhoven MA; Schinkel AH; Schellens JH
Cancer Chemother Pharmacol; 2005 Oct; 56(4):344-50. PubMed ID: 15875186
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
12. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
13. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
[TBL] [Abstract][Full Text] [Related]
14. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
16. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
18. Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems.
Lee G; Babakhanian K; Ramaswamy M; Prat A; Wosik K; Bendayan R
Pharm Res; 2007 Jul; 24(7):1262-74. PubMed ID: 17380269
[TBL] [Abstract][Full Text] [Related]
19. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Ee PL; He X; Ross DD; Beck WT
Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
[TBL] [Abstract][Full Text] [Related]
20. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
